HomeCompareRSLBF vs EQR

RSLBF vs EQR: Dividend Comparison 2026

RSLBF yields 1.37% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $18.8K in total portfolio value
10 years
RSLBF
RSLBF
● Live price
1.37%
Share price
$23.00
Annual div
$0.31
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$149.57
Full RSLBF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — RSLBF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSLBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSLBF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSLBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSLBF
Annual income on $10K today (after 15% tax)
$116.34/yr
After 10yr DRIP, annual income (after tax)
$127.13/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $3,119.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSLBF + EQR for your $10,000?

RSLBF: 50%EQR: 50%
100% EQR50/50100% RSLBF
Portfolio after 10yr
$31.1K
Annual income
$1,984.58/yr
Blended yield
6.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RSLBF
No analyst data
Altman Z
6.1
Piotroski
7/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSLBF buys
0
EQR buys
0
No recent congressional trades found for RSLBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSLBFEQR
Forward yield1.37%4.73%
Annual dividend / share$0.31$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$21.6K$40.5K
Annual income after 10y$149.57$3,819.61
Total dividends collected$1.4K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RSLBF vs EQR ($10,000, DRIP)

YearRSLBF PortfolioRSLBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,837$136.87$11,248$547.57$411.00EQR
2$11,734$138.62$12,701$666.53$967.00EQR
3$12,696$140.28$14,405$814.59$1.7KEQR
4$13,726$141.84$16,413$999.84$2.7KEQR
5$14,830$143.33$18,795$1,232.92$4.0KEQR
6$16,013$144.72$21,639$1,527.95$5.6KEQR
7$17,280$146.04$25,057$1,903.80$7.8KEQR
8$18,637$147.29$29,197$2,385.87$10.6KEQR
9$20,090$148.46$34,250$3,008.70$14.2KEQR
10$21,646$149.57$40,467$3,819.61$18.8KEQR

RSLBF vs EQR: Complete Analysis 2026

RSLBFStock

RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.

Full RSLBF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RSLBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSLBF vs SCHDRSLBF vs JEPIRSLBF vs ORSLBF vs KORSLBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.